It's unclear to me how much of any given trial is covered by a grant. I don't believe we can advance them all with $7M cash + grants. The grant amounts seem small and while they will improve our financial efficiency I don't think they are a primary funding mechanism.
This is why Prurisol results are so critical.
If Good, we decide which of our good funding options to take:
1. Partner/License Prurisol for all the cash we will need for all trials we would like to start. or 2. Sell stock with a significantly higher share price and keep Prurisol for phase 3 development.
If Bad, we decide between the crap options:
1. Sell to Aspire for just the money we need for B P3 and put other trials on hold. or 2. Decide it's worth notable dilution to continue pushing all of our trials.
News 
Market Data 
Discover 
AI
